Harry Erba, MD, PhD

    Harry Erba, MD, PhD

    Director of the UAB Hematologic Malignancy Program at the University of Alabama at Birmingham
    • Teaching Old Drugs New Tricks? Thursday, March 1st, 2018

      When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new again. The drug, which is a combination of two existing generic drugs encased in a liposome, received breakthrough-therapy designation in August 2017 for the treatment of adults with newly diagnosed, therapy-related [...]

    SHARE